Aldeyra Therapeutics, Inc.

3.45 USD
-0.03 (-0.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aldeyra Therapeutics, Inc. stock is down -8.97% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 June’s closed higher than May.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.